Visiongain Publishes Cellular Immunotherapy Market Report 2021-2031

15 June 2021
Pharma

Visiongain has published a new report entitled the Cellular Immunotherapy Market Report 2021-2031: Forecasts by Therapy Type (CAR-T Cell Therapy, NK Cell Therapy, TIL Therapy, Others), by Products & Services (Cellular Immunotherapy Products, Cellular Immunotherapy Services), by Testing Assays Type (Bioanalytics, Characterization, Biosafety), by Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cellular Immunotherapy Companies AND COVID-19 Recovery Scenarios.

The global cellular immunotherapy drugs market was valued at US$ US$xx bn in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. The rising geriatric population, increasing prevalence of cancers, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced therapies for cancer treatment are some of the major factors that drive the growth of the global cellular immunotherapy market.

How has COVID-19 had a significant negative impact on the Cellular Immunotherapy Market?
The COVID-19 pandemic has a negative impact on the cellular immunotherapy market worldwide. The COVID-19 pandemic has resulted in the decreasing R&D related to cellular immunotherapy and issues with product delivery worldwide due to lockdown and insufficient supply of raw material. The pharmaceutical companies are facing challenges while R&D, manufacturing, and marketing due to the COVID-19 pandemic. According to the WHO, the COVID-19 pandemic has disturbed the healthcare services in many countries.

Drug development and manufacturing have been worldwide efforts, with China and India becoming as key players in the global pharmaceutical supply chain. Companies are concerned about the COVID-19 epidemic's impact on supply and demand. All of these factors are having a negative impact on the cellular immunotherapy sector, pushing the pharmaceutical industry and regulators to re-examine pharmaceutical supply chains.

How this Report Will Benefit you?
Visiongain’s 460+ page report provides 280 tables and 266 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global cellular immunotherapy market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for cellular immunotherapy. Get the financial analysis of the overall market and different segments including therapy type, product & services, indication, and testing assay type and capture higher market share. We believe that high opportunity remains in this fast-growing cellular immunotherapy market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the current market drivers?
Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies. According to the International Agency for Research on Cancer, 1 in 5 people will develop cancer during their lifetime, with 1 in 8 men and 1 in 11 women being affected. These recent figures indicate that more than 50 million people are living within five years of a previous cancer diagnosis.

The older population in the world is growing constantly at an unprecedented rate. At present, around 8.5% population in the world is aged 65 and over accounting for more than 615 million. Since older people are prone to developing cancer, the aging population leads to a higher number of patients living with cancer. The rising geriatric population burden is posing a public health challenge. As the aging population is increasing, the demand for advanced cancer therapies is also growing which is expected to drive the market during the forecast period.

Where are the market opportunities?
The R&D investment for the development of more advanced cellular immunotherapy is the major factor that will boost the market growth during the forecast period 2021-2031. Increasing research in the field of biological science has led many researchers to believe that biological therapies such as personalized medicines, monoclonal antibodies, and biosimilar drugs prove to treat the disease in a much better way. Rising investment in the field of R&D is therefore seen by major developers to initiate and commercialize these techniques for the treatment of cancer.

The developing healthcare infrastructure in emerging economies, rising incidence of cancer, rising popularity of advanced cellular immunotherapy, and government support for cellular therapies R&D are expected to boost the cellular immunotherapy market growth. Technical advances in manufacturing methods and improvements in CAR-T-cell therapy for solid tumors are expected to drive market growth.

Competitive Landscape
The major players operating in the cellular immunotherapy market are Novartis AG; Gilead Sciences, Inc.; Adicet Bio; GlaxoSmithKline plc.; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Iovance Biotherapeutics, Inc.; Tessa Therapeutics Ltd.; Inovio Pharmaceuticals, Inc.; AstraZeneca;Adaptimmune Therapeutics plc.; Atara Biotherapeutics, Inc.;Bristol-Myers Squibb Company; APAC Biotech; and JW shinyak (JW CreaGene).

Strategic collaboration, R&D investment, and geographic development are some of the primary strategies used by the market's leading companies to gain the largest revenue share. For instance, In April 2020, Novartis received the US FDA granted Regenerative Medicine Advanced Therapy designation for its Kymriah (tisagenlecleucel).

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever